Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Antibody

NCT04921358 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT04921358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04921358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Antibody
Lead sponsor
BeiGene
Phase
Phase 3
Overall status
Terminated
Start date
July 27, 2021
Completion date
December 20, 2023
Enrollment
377 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)